Administration of the approved drug milrinone via venous access to treat and to prevent vasospasm

Intravenous application of milrinone for the treatment and prophylaxis of SAB induced vasospasm

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-016620-32-AT

Enrollment

100

Registered

2012-07-24

Start date

2012-08-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SAB-induced vasospasm

Interventions

Trade Name: Corotrop Product Name: Milrinon Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: Milrinone CAS Number: 100286-97-3 Other descriptive name: MILRIN

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -) male or female -) 18 > age =65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: -) cerebral aneurysm -) intracerbral or interventricular bleeding in absence of SAB -) persistent vasospasm -) severe complication at primary care of the bleeding -) cereral pressure > 20 mmHg -) impaired blood coagulation

Design outcomes

Primary

Measure	Time frame
Main Objective: Reduction of the relative risk of the occurence vasospasms of about 30% in the treatment group ;Secondary Objective: -) total volume of newly occured insults 6 weeks after SAB -) modified Rankin scale -) cognitive function 12 weeks after SAB;Primary end point(s): Glasgow Outcome Scale Extended (GOSE) - 12 weeks after SAB;Timepoint(s) of evaluation of this end point: 12 weeks after SAB	—

Measure

Time frame

Main Objective: Reduction of the relative risk of the occurence vasospasms of about 30% in the treatment group ;Secondary Objective: -) total volume of newly occured insults 6 weeks after SAB -) modified Rankin scale -) cognitive function 12 weeks after SAB;Primary end point(s): Glasgow Outcome Scale Extended (GOSE) - 12 weeks after SAB;Timepoint(s) of evaluation of this end point: 12 weeks after SAB

—

Secondary

Measure	Time frame
Secondary end point(s): -) Total volume of new insults -) modified Rankin scale -) cognitive capability using a patient-reported questionnaire;Timepoint(s) of evaluation of this end point: 12 weeks after onset of SAH	—

Countries

Austria

Contacts

Public ContactDept. of Neurological Surgery

Dept. of Neurological Surgery, Medical University of Vienna

christian.schnuerer@meduniwien.ac.at00431404002565

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Apr 4, 2026